NTRK1 and Alzheimer disease: In this context, constant adaptations in the delivery mode to CNS and in the drug-design pharmacological approach with the development of TrkA mimetics have recently allowed to achieve significant results in increasing the NGF bioavailability to target neurons and/or in reducing its potential indirect and unwanted side-effects (Mufson et al., 2008) with consequent long-term improvement of the cholinotrophic basal forebrain function affected in AD patients (Mufson et al., 2008).